Theratechnologies Inc (THTX) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access THTX Annual Income Statement →
Observing income statement movements over recent quarters helps explain how Theratechnologies Inc adapts pricing, costs, and operating efficiency.
Quarterly Report, GAAP in USD millions
ITEM
(Nov 30 2024)
Q4 2024
0 0 0 (Nov 30 2023)
Revenues
Total Revenue85.87
Costs & Expenses
Cost of Goods and Services Sold20.45
Gross Profit65.42
Selling, Administration, Marketing25.42
Other Operating Expense / -Income31.83
Total operating costs including COS77.69
Operating income / -loss8.17
Net Interest Expense / -Income0.00
Other loss / -income-14.48
Total costs & expenses92.17
Income & Taxes
Income / -loss before income taxes-6.30
Income taxes expenses / -benefit2.01
Income after income taxes-8.31
Net income / -loss of other equity0.00
Income / -loss from continuing operations-8.31
Net income / -loss-8.31
Income / -loss to shareholder-8.31
EBIT-6.30
EBITD-5.32
EBITDA-3.88
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)0.00
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)0.00
4 historic quarters locked

Sign in to unlock the full Theratechnologies Inc income statement history.

About THTX Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.